As filed with the Securities
and Exchange Commission on November 9, 2020.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
FORTRESS BIOTECH, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
2834
|
47-3828760
|
(State
or Other Jurisdiction of
Incorporation or Organization)
|
(Primary
Standard Industrial
Classification Code Number)
|
(I.R.S.
Employer
Identification
Number)
|
2 Gansevoort Street, 9th Floor
New York, New York 10014
(781) 652-4500
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal
Executive Offices)
Lindsay A. Rosenwald, M.D.
Executive Chairman,
Chief Executive Officer and President
2 Gansevoort Street, 9th Floor
New York, New York 10014
(781) 652-4500
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
Copies to:
Mark McElreath
Alston & Bird LLP
90 Park Avenue
New York, NY 10016
(212) 210-9400
Approximate date of commencement
of proposed sale to the public: From time to time after the effective date of this Registration Statement.
If the only securities being registered
on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ¨
If any of the securities being registered
on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box. x
If this form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. ¨
If this form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. ¨
If this Form is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. ¨
If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ¨
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller
reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨
|
Accelerated filer x
|
Non-accelerated filer ¨
|
Smaller reporting company x
|
|
Emerging growth company ¨
|
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ¨
CALCULATION OF REGISTRATION
FEE
Title of Each Class of Securities to be Registered
|
|
Amount to be
Registered(1)
|
|
|
Proposed Maximum
Offering Price per
Unit(2)
|
|
|
Proposed
Maximum
Aggregate Offering
Price(2)
|
|
|
Amount of
Registration Fee
|
|
Common Stock, par value $0.001 per share
|
|
|
2,100,000
|
|
|
$
|
2.40
|
|
|
$
|
5,040,000.00
|
|
|
$
|
549.86
|
|
|
(1)
|
The Registrant
is hereby registering for resale from time to time by the selling stockholders named
herein of up to 2,100,000 shares of common stock issuable upon exercise of warrants
granted to the selling stockholders, all of which were initially granted in connection
with a senior secured credit agreement, dated as of August 27, 2020, by and among
the Registrant, Oaktree Fund Administration, LLC as the administrative agent, and the
selling stockholders and other the lenders from time to time party thereto (the “Credit
Agreement”). Pursuant to Rule 416(a) under the Securities Act of 1933, as
amended, or the Securities Act, this registration statement also covers such additional
number of shares of common stock that may be issued as a result of stock splits, stock
dividends, anti-dilution issuances, or similar transactions.
|
|
(2)
|
Estimated solely for purposes of determining the registration
fee pursuant to Rule 457(c) under the Securities Act. The proposed maximum offering price per share and proposed maximum
aggregate offering price shown are based on the average of the high and low sale prices of the Registrant’s common
stock on November 5, 2020 as reported on The Nasdaq Capital Market.
|
The Registrant hereby
amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the
Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The information in this
prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities
until the registration statement becomes effective. This prospectus is not an offer to sell these securities, and the selling stockholders
named in this prospectus are not soliciting offers to buy these securities in any jurisdiction where the offer for sale is not
permitted.
Subject To Completion,
Dated November 9, 2020
PROSPECTUS
2,100,000 Shares of Common Stock
This prospectus relates to the resale by
the selling stockholders named herein, or their pledgees, donees, transferees or other successors in interest, from time to time,
of up to 2,100,000 shares of our common stock issuable upon exercise of warrants granted to the selling stockholders in connection
with the senior secured credit agreement dated as of August 27, 2020, or the Credit Agreement, by and among Fortress Biotech,
Inc., Oaktree Fund Administration, LLC as the administrative agent, and the selling stockholders and other the lenders from time
party thereto. The shares of Company common stock issuable upon exercise of the warrants are referred to herein as the Securities.
We are registering the Securities on behalf of the selling stockholders, to be offered and sold from time to time, to satisfy certain
registration rights that we have granted to the selling stockholders.
The selling stockholders may resell or
dispose of the Securities, or interests therein, at fixed prices, at prevailing market prices at the time of sale or at prices
negotiated with purchasers, to or through underwriters, broker-dealers, agents, or through any other means described in the section
of this prospectus entitled “Plan of Distribution”. The selling stockholders will each bear their respective commissions
and discounts, if any, attributable to the sale or disposition of the Securities, or interests therein, held by such selling stockholder.
We will bear all costs, expenses and fees in connection with the registration of the Securities. We will not receive any of the
proceeds from the sale of the Securities by the selling stockholders.
Our common stock, par value $0.001, is
listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “FBIO.” On November 6, 2020, the last reported sale
price of our Common Stock was $2.31 per share. You are urged to obtain current market quotations for our common stock.
Investing in our Securities involves
risks. You should review carefully the risks and uncertainties described under the heading “Risk Factors” contained
in this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus as
described on page 3 of this prospectus.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy
of this prospectus. Any representation to the contrary is a criminal offense.
The date of this Prospectus is ,
2020
Table of
Contents
ABOUT THIS PROSPECTUS
This prospectus provides you with a general
description of the Securities that may be resold by the selling stockholders. In certain circumstances, we may provide a prospectus
supplement that will contain specific information about the terms of a particular offering by the selling stockholders. We also
may provide a prospectus supplement to add information to, or update or change information contained in, this prospectus. To the
extent there is a conflict between the information contained in this prospectus and the prospectus supplement, you should rely
on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with
a statement in another document having a later date — for example, a document incorporated by reference in
this prospectus or any prospectus supplement — the statement in the later-dated document modifies or supersedes
the earlier statement.
You should read both this prospectus and
any applicable prospectus supplement together with the additional information about our company to which we refer you in the sections
of this prospectus entitled “Where You Can Find More Information” and “Incorporation of Certain Information by
Reference.” You should rely only on the information contained in or incorporated by reference into this prospectus and any
prospectus supplement. Neither we nor the selling stockholders have authorized any dealer, sales person or other person to provide
you with different information. You should not assume that the information in this prospectus or any prospectus supplement is accurate
as of any date other than the date on the front of those documents or that any document incorporated by reference is accurate as
of any date other than its filing date. You should not consider this prospectus to be an offer or solicitation relating to the
Securities in any jurisdiction in which such an offer or solicitation relating to the Securities is not authorized. Furthermore,
you should not consider this prospectus to be an offer or solicitation relating to the Securities if the person making the offer
or solicitation is not qualified to do so, or if it is unlawful for you to receive such an offer or solicitation.
Unless the context indicates otherwise,
when we refer to “Fortress,” “we,” “our,” “us” and the “Company” in
this prospectus, we mean Fortress Biotech, Inc., unless otherwise specified. When we refer to “you,” we mean the potential
holders of the applicable series of Securities.
FORWARD-LOOKING STATEMENTS
This prospectus, including
the documents that we incorporate by reference, may contain forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended,
or the Exchange Act. Statements in this prospectus, and documents we incorporate by reference, that are not descriptions of historical
facts are forward-looking statements that are based on management’s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock price. We have attempted to identify
forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,”
“could,” “estimates,” “expects,” “intends,” “may,” “might,”
“plans,” “potential,” “predicts,” “should,” or “will” or the negative
of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently
anticipated include those set forth under “Risk Factors” including, in particular, risks relating to:
|
·
|
our ability to continue to commercialize products;
|
|
·
|
our ability to identify, acquire, close and integrate product candidates and companies successfully
and on a timely basis;
|
|
·
|
financing and strategic agreements, acquisitions and relationships;
|
|
·
|
our need for substantial additional funds and uncertainties relating to financings;
|
|
·
|
our ability to attract, integrate and retain key personnel;
|
|
·
|
the early stage of products under development;
|
|
·
|
the results of research and development activities;
|
|
·
|
uncertainties relating to preclinical and clinical testing;
|
|
·
|
our ability to secure and maintain third-party manufacturing, marketing and distribution of our
products;
|
|
·
|
dependence on third-party suppliers;
|
|
·
|
patent and intellectual property matters; and
|
You should read this
prospectus and the documents that we reference herein completely and with the understanding that our actual future results may
be materially different from what we currently expect. You should assume that the information appearing in this prospectus and
any document incorporated by reference is accurate as of its date only. Because the risk factors referred to above could cause
actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf,
you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of
the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances
after the date on which the statement is made or to reflect the occurrence of unanticipated events, and we claim the protection
of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. New factors
emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the
impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this prospectus,
any accompanying prospectus supplement and any document incorporated herein by reference, and particularly our forward-looking
statements, by these cautionary statements.
SUMMARY
The
following summary highlights information contained elsewhere in this prospectus. This summary is not complete and does not contain
all of the information that you need to consider before making an investment decision. For a more complete understanding of our
company, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus
and any applicable prospectus supplement, including the factors described under the heading “Risk Factors” beginning
on page 3 of this prospectus, as well as the information incorporated by reference from our most recent Annual Report on Form
10-K and our most recent Quarterly Reports on Form 10-Q, before making an investment decision.
Overview
Fortress Biotech, Inc.
(“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing
pharmaceutical and biotechnology products and product candidates, which the Company does at the Fortress level, at its majority-owned
and majority-controlled subsidiaries and joint ventures, and through entities that the Company founded and in which it maintains
significant minority ownership positions (which we sometimes refer to as “partner companies”). Fortress has a talented
and experienced business development team comprising scientists, doctors and finance professionals, who identify and evaluate promising
products and product candidates for potential acquisition by new or existing partner companies. Fortress, through its partner companies,
has executed such arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical
companies, including City of Hope National Medical Center, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research
Hospital, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Cincinnati Children’s Hospital Medical Center,
Columbia University, the University of Pennsylvania, and AstraZeneca plc.
Business Strategy
Following the exclusive
license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business,
scientific, regulatory, legal and finance expertise to help the partners achieve their goals. Partner companies then assess a broad
range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint
ventures, partnerships, out-licensings, and public and private financings; to date, three partner companies are publicly-traded,
and two have consummated strategic partnerships with industry leaders Alexion Pharmaceuticals, Inc. and InvaGen Pharmaceuticals,
Inc. (a subsidiary of Cipla Limited).
As of September 30,
2020, several of the Fortress partner companies maintain licenses to product candidate intellectual property, including Aevitas
Therapeutics, Inc. (“Aevitas”), Avenue Therapeutics, Inc. (“Avenue”), Baergic Bio, Inc. (“Baergic”),
Caelum Biosciences, Inc. (“Caelum”), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (“Checkpoint”),
Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (“Journey”
or “JMC”), Mustang Bio, Inc. (“Mustang”) and Oncogenuity, Inc. (“Oncogenuity”).
Our principal executive
offices are located at 2 Gansevoort Street, 9th Floor, New York, New York 10014, and our telephone number is 781-652-4500. We maintain
a website on the internet at www.fortressbiotech.com and our e-mail address is info@fortressbiotech.com. Our internet website,
and the information contained on it, are not to be considered part of this prospectus.
Grant of Warrants
On August 27,
2020, we entered into a senior secured credit agreement with Oaktree Fund Administration, LLC, as the administrative agent, and
the selling stockholders and other the lenders from time party thereto, or the Credit Agreement, in connection with which, in relevant
part, we granted to the selling stockholders 1,749,450 warrants to purchase shares of our common stock at a one to one ratio with
an exercise price per share of $3.20. The warrants may be net exercised at each holder’s election and have a ten-year term.
In addition, in connection
with the Credit Agreement, we entered into a registration rights agreement with the selling stockholders, or the Registration Rights
Agreement, in which we agreed to prepare and file with the SEC a registration statement with respect to resales of the Securities
purchased by the selling stockholders in connection with the Credit Agreement. Accordingly, as required by the Registration Rights
Agreement, the registration statement of which this prospectus is a part relates to the offer and resale of the Securities issued
to the selling stockholders in connection with the Credit Agreement.
THE OFFERING
Issuer
|
Fortress Biotech, Inc.
|
|
|
Securities Offered by Selling Stockholders
|
2,100,000 shares of Company common
stock, issuable upon the exercise of warrants to purchase Company common stock, granted to the selling stockholders in connection
with the terms of the Credit Agreement.
|
|
|
Terms of the Company Warrants
|
Each warrant entitles the selling stockholders to purchase one share of Company common stock, subject to any adjustments, at an exercise price of $3.20 per share. The Company warrants may be net exercised at each selling stockholder’s election and have a ten-year term.
|
|
|
Terms of the offering
|
The selling stockholders will each determine when and how they will sell the Securities offered in this prospectus, as described in the “Plan of Distribution.”
|
|
|
Use of proceeds
|
We will not receive any proceeds from the sale of the Securities by the selling stockholders in this offering. See “Use of Proceeds.”
|
|
|
Risk factors
|
See “Risk Factors” beginning on page 3 and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.
|
|
|
Nasdaq Capital Market symbol
|
FBIO.
|
RISK FACTORS
Investing in our securities
involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described in the
sections entitled “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on
Form 10-Q, as filed with the SEC, which are incorporated herein by reference in their entirety, as well any amendment or updates
to our risk factors reflected in subsequent filings with the SEC, including any applicable prospectus supplement. For a description
of these reports and documents, and information about where you can find them, see “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference.” Each of the risk factors could adversely affect our business,
results of operations, financial condition and cash flows, as well as adversely affect the value of an investment in our securities,
and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently
known to us or that we currently believe are immaterial may also significantly impair our business operations.
USE OF PROCEEDS
We will not receive
any proceeds from the sale of the Securities covered by this prospectus and any accompanying prospectus supplement. All proceeds
from the sale of the Securities will be for the respective accounts of the selling stockholders named herein.
We
will bear all other costs, fees and expenses incurred in effecting the registration of the Securities covered by this prospectus
and any accompanying prospectus supplement, including, without limitation, all registration and filing fees, Nasdaq listing fees
and fees and expenses of our counsel and our accountants, in accordance with the terms of the Registration Rights Agreement entered
into by and among the Company and the selling stockholders in connection with the Credit Agreement on August 27, 2020. Each selling
stockholder will each pay any discounts, commissions, and fees of underwriters, selling brokers, dealer managers or similar securities
industry professionals incurred by such selling stockholder in disposing of the Securities covered by this prospectus.
THE SELLING STOCKHOLDERS
We have prepared this
prospectus to allow the selling stockholders or their pledgees, donees, transferees or other successors in interest, to sell or
otherwise dispose of, from time to time, up to 2,100,000 shares of Company common stock issuable pursuant to Company warrants
granted to the selling stockholders.
On August 27,
2020, we entered into the Credit Agreement with Oaktree Fund Administration, LLC as the administrative agent, and the selling stockholders
and other the lenders from time party thereto, in connection with which we granted to the selling stockholders an aggregate of
1,749,450 warrants to purchase Company common stock with an exercise price per share of $3.20. In connection with certain registration
rights that we granted to the selling stockholders pursuant to the Registration Rights Agreement, we filed with the SEC a registration
statement on Form S-3, of which this prospectus forms a part, with respect to the resale or other disposition of the Securities
offered by this prospectus from time to time on Nasdaq, in privately negotiated transactions or otherwise. We have agreed to prepare
and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective
for the period of time required under our agreement with the selling stockholders.
The following table
sets forth the names of each of the selling stockholders and the aggregate number of Securities that the selling stockholders may
offer and sell pursuant to this prospectus. The selling stockholders may sell some, all or none of the Securities. We do not know
how long the selling stockholders will hold the Securities before selling them, and we currently have no agreements, arrangements
or understandings with any selling stockholder regarding the sale or other disposition of any of the Securities. The Securities
may be offered and sold from time to time by the selling stockholders pursuant to this prospectus. The information below assumes
the offer and sale of all Securities beneficially owned by the selling stockholders and available for sale under this prospectus
and assumes no further acquisitions or dispositions of Securities by the selling stockholders.
|
|
Before Offering
|
|
|
After Offering
|
|
Name and Address of Selling
Stockholder(1)
|
|
|
Number
of
Shares of
Common Stock
Beneficially
Owned (2)(3)
|
|
|
|
Number of
Shares of
Common Stock
Offered(3)
|
|
|
|
Number of
Shares of
Common Stock
Beneficially
Owned
|
|
|
|
Percentage of
Shares of
Common Stock
Beneficially
Owned
|
|
Oaktree-TCDRS Strategic Credit, LLC
|
|
|
83,099
|
|
|
|
83,099
|
|
|
|
—
|
|
|
|
—
|
|
Exelon Strategic Credit Holdings, LLC
|
|
|
49,772
|
|
|
|
49,772
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-NGP Strategic Credit, LLC
|
|
|
83,420
|
|
|
|
83,420
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-Minn Strategic Credit, LLC
|
|
|
40,296
|
|
|
|
40,296
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-Forrest Multi-Strategy, LLC – Series A
|
|
|
67,908
|
|
|
|
67,908
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-TBMR Strategic Credit Fund C, LLC
|
|
|
39,333
|
|
|
|
39,333
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-TBMR Strategic Credit Fund F, LLC
|
|
|
61,377
|
|
|
|
61,377
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-TBMR Strategic Credit Fund G, LLC
|
|
|
100,506
|
|
|
|
100,506
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree-TSE 16 Strategic Credit, LLC
|
|
|
76,684
|
|
|
|
76,684
|
|
|
|
—
|
|
|
|
—
|
|
INPRS Strategic Credit Holdings, LLC
|
|
|
33,589
|
|
|
|
33,589
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree Gilead Investment Fund AIF (Delaware), L.P.
|
|
|
300,643
|
|
|
|
300,643
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree Huntington-GCF Investment Fund (Direct Lending AIF), L.P.
|
|
|
29,302
|
|
|
|
29,302
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree Strategic Income II, Inc.
|
|
|
85,811
|
|
|
|
85,811
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree Specialty Lending Corporation
|
|
|
243,348
|
|
|
|
243,348
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree Strategic Income Corporation
|
|
|
87,852
|
|
|
|
87,852
|
|
|
|
—
|
|
|
|
—
|
|
Oaktree PRE Life Sciences Fund, L.P.
|
|
|
366,510
|
|
|
|
366,510
|
|
|
|
—
|
|
|
|
—
|
|
|
(1)
|
The
principal business address and address for notice of the selling stockholders is 333
S. Grand Avenue, 28th Fl., Los Angeles, California, 90071.
|
|
(2)
|
“Beneficial
ownership” is a term broadly defined by the SEC in Rule 13d-3 under the Exchange
Act, and includes more than the typical form of stock ownership, that is, stock held
in the person’s name. The term also includes what is referred to as “indirect
ownership,” meaning ownership of shares as to which a person has or shares investment
power. For purposes of this table, a person or group of persons is deemed to have “beneficial
ownership” of any shares that are currently exercisable or exercisable within 60
days of October 1, 2020.
|
|
(3)
|
Consists
solely of shares of Company common stock issuable upon exercise of a warrant granted
to each selling stockholder in connection with the Credit Agreement, dated as of August
27, 2020, exercisable into the exact number of shares of Company common stock set forth
for each selling stockholder.
|
Relationship with
the Selling Stockholders
Credit Agreement
As discussed above
under the section “Summary — Grant of Warrants,” on August 27, 2020, we entered into the Credit
Agreement with the lenders from time to time party thereto, in connection with which we granted to the selling stockholders an
aggregate of 1,749,450 warrants exercisable into shares of Company common stock, with an exercise price per share of $3.20.
Registration Rights
Agreement
Pursuant to the Registration
Rights Agreement with the selling stockholders, we agreed to prepare and file with the SEC the registration statement of which
this prospectus forms a part that permits the resale of the Securities and, subject to certain exceptions, use reasonable best
efforts to keep such registration statement effective under the Securities Act until (i) all Securities registered by the registration
statement have been sold, transferred or otherwise disposed of by the selling stockholders, (ii) the Securities are sold, transferred
or otherwise disposed of pursuant to Rule 144 of the Securities Act, or (iii) the Securities have become eligible for sale by the
selling stockholders pursuant to Rule 144 without any restriction on the volume or manner of such sale and all restrictive legends
and stop transfer instructions have been removed with respect to all book entries representing the Securities.
We have also agreed,
among other things, to indemnify the selling stockholders and their officers, directors, members, employees and agents, successors
and assigns, and any person who controls either of the selling stockholders (within the meaning of the Securities Act or the Exchange
Act) from all losses and liabilities arising under the registration statement of which this prospectus forms a part and any securities
laws applicable to the registration statement of which this prospectus forms a part and to pay all fees and expenses (including
all reasonable costs of preparation and reasonable attorneys’, accountants’ and experts’ fees).
Warrants
The warrants are exercisable
at any time on or after the date of issuance and entitle the selling stockholders to purchase shares of our common stock for a
period of ten years from the date of issuance at a price per share equal to $3.20 per share, subject to certain adjustments.
Except as described
above, neither the selling stockholders nor any persons having control over such selling stockholders have held any position or
office with us or our affiliates within the last three years or has had a material relationship with us or any of our predecessors
or affiliates within the past three years, other than as a result of the ownership of shares of our common stock or other
securities.
DESCRIPTION OF CAPITAL STOCK
The following description
summarizes the material terms of Fortress capital stock as of the date of this registration statement. Because it is only a summary,
it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
refer to our certificate of incorporation, our bylaws and to the provisions of applicable Delaware law.
Common Stock
Our common stock is
traded on The Nasdaq Capital Market under the symbol “FBIO.” The last reported sale price of our common stock on November
6, 2020 was $2.31 per share.
The Company’s
Certificate of Incorporation, as amended, authorizes the Company to issue 150,000,000 shares of $0.001 par value common
stock of which 93,702,861 shares were outstanding at September 30, 2020.
The terms, rights,
preference and privileges of our common stock are as follows:
Voting Rights
Each holder of our
common stock is entitled to one vote per share of common stock held on all matters submitted to a vote of the stockholders, including
the election of directors. The Company’s certificate of incorporation and bylaws do not provide for cumulative voting rights.
Dividends
Subject to preferences
that may be applicable to any then-outstanding preferred stock, the holders of the Company’s outstanding shares of common
stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s Board of Directors
out of legally available funds.
Liquidation
In the event of the
Company’s liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of the Company’s debts and other liabilities,
subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.
Rights and Preference
Holders of the Company’s
common stock have no preemptive, conversion or subscription rights, and there is no redemption or sinking fund provisions applicable
to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely
affected by, the rights of the holders of shares of any series of the Company’s preferred stock that are or may be issued.
Fully Paid and Nonassessable
All of the Company’s
outstanding shares of common stock are fully paid and nonassessable.
PLAN OF DISTRIBUTION
The
selling stockholders, including their pledgees, donees, transferees, distributees, beneficiaries or other successors in interest,
may from time to time offer some or all of the Securities by this prospectus. We will not receive any of the proceeds from the
sale of the Securities covered by this prospectus by the selling stockholders. The selling stockholders will act independently
of us in making decisions with respect to the timing, manner and size of each sale. We will bear all fees and expenses incident
to our obligation to register the Securities covered by this prospectus.
The
selling stockholders may each sell all or a portion of the Securities beneficially owned by it and offered hereby from time to
time directly or through one or more underwriters, broker-dealers or agents. If the Securities are sold through underwriters or
broker-dealers, the selling stockholders will each be responsible for underwriting discounts or commissions or agent’s commissions
in connection with the Securities held by such selling stockholders. The Securities may be sold on any national securities exchange
or quotation service on which the Securities may be listed or quoted at the time of sale, in the over-the-counter market or in
transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at
fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at privately
negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions.
The
selling stockholders may use any one or more of the following methods when disposing of Securities or interests therein:
|
·
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
·
|
block trades in which the broker-dealer will attempt to sell the Securities as agent, but may position
and resell a portion of the block as principal to facilitate the transaction
|
|
·
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
·
|
an over-the-counter distribution;
|
|
·
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
|
·
|
privately negotiated transactions;
|
|
·
|
short sales effected after the effective date of the registration statement of which this prospectus
is a part;
|
|
·
|
through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;
|
|
·
|
in “at the market” offerings, as defined in Rule 415 under the Securities Act,
at negotiated prices, at prices prevailing at the time of sale or prices related to such prevailing market prices, including sales
made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar
offerings through sales agents;
|
|
·
|
through trading plans entered into by the selling stockholders pursuant to Rule 10b5-1 under
the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement
hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans;
|
|
·
|
through firm-commitment underwritten public offerings;
|
|
·
|
a combination of any such methods of sale; or
|
|
·
|
any other method permitted pursuant to applicable law.
|
The selling stockholders
may each, from time to time, pledge or grant a security interest in some or all of the Securities owned and, if any selling stockholder
defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the Securities, from
time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision
of the Securities Act amending the list of the selling stockholders to include the pledgee, transferee, or other successors in
interest as the selling stockholders under this prospectus. The selling stockholders also may transfer the Securities in other
circumstances, in which case the transferees, pledgees or other successors in interest will be the beneficial owners for purposes
of this prospectus.
In connection with
the sale of Securities, or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the Common Stock in the course of hedging the positions
it assumes. The selling stockholders may also sell Securities short and deliver the Securities to close out any such short positions,
or loan or pledge the Securities to broker-dealers that in turn may sell these Securities. The selling stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative
securities which require the delivery to such broker-dealer or other financial institution of Securities offered by this prospectus,
which Securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).
Broker-dealers engaged
by the selling stockholders may arrange for other broker-dealers to participate in sales. If the selling stockholders effect certain
transactions by selling Securities to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
may receive commissions in the form of discounts, concessions or commissions from such selling stockholders or commissions from
purchasers of the Securities for whom they may act as agent or to whom they may sell as principal. Such commissions will be in
amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will
not be in excess of a customary brokerage commission in compliance with applicable rules of the Financial Industry Regulatory Authority,
or FINRA, and in the case of a principal transaction, a markup or markdown in compliance with applicable FINRA rules.
The aggregate proceeds
to the selling stockholders from the sale of the Securities offered will be the purchase price of the Securities less discounts
or commissions, if any. The selling stockholders reserve the right to accept and, together with their respective agents from time
to time, to reject, in whole or in part, any proposed purchase of Securities to be made directly or through agents. The selling
stockholders also may resell all or a portion of the Securities in open market transactions in reliance upon Rule 144 under
the Securities Act, rather than under this prospectus, provided that each meets the criteria and conforms to the requirements of
that rule.
The selling stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the Securities, or interests therein, may be deemed
to be “underwriters” within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions,
concessions or profit they earn on any resale of the Securities may be underwriting discounts and commissions under the Securities
Act. The selling stockholders are subject to the prospectus delivery requirements of the Securities Act.
To the extent required
pursuant to Rule 424(b) under the Securities Act, the Securities to be sold, the names of the selling stockholders, the purchase
price and public offering price, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with
respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment
to the registration statement that includes this prospectus.
In order to comply
with the securities laws of some states, if applicable, the Securities may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the Securities may not be sold unless they have been registered or
qualified for sale, or an exemption from registration or qualification requirements is available and the selling stockholder complies
with such exemption’s requirements.
The selling stockholders
and any other person participating in a sale of the Securities registered under this prospectus will be subject to applicable provisions
of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M
of the Exchange Act, which may limit the timing of purchases and sales of any of the Securities by the selling stockholders and
any other participating person. All of the foregoing may affect the marketability of the Securities and the ability of any person
or entity to engage in market-making activities with respect to the Securities. In addition, we will make copies of this prospectus
(as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the
prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates
in transactions involving the sale of the Securities against certain liabilities, including liabilities arising under the Securities
Act.
LEGAL MATTERS
Certain legal matters
will be passed upon for us by Alston & Bird LLP, New York, New York. Additional legal matters may be passed upon for us or
any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.
EXPERTS
The financial
statements as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019 and
management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2019,
incorporated by reference in this Prospectus, have been so incorporated in reliance on the reports of BDO USA, LLP, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as
experts in auditing and accounting.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with
the SEC a registration statement on Form S-3 under the Securities Act with respect to the Securities offered hereby. This prospectus
does not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. For further
information with respect to the Company and its Securities, reference is made to the registration statement and the exhibits and
any schedules filed therewith. Statements contained in this prospectus as to the contents of any contract or other document referred
to are not necessarily complete and in each instance, if such contract or document is filed as an exhibit, reference is made to
the copy of such contract or other document filed as an exhibit to the registration statement, each statement being qualified in
all respects by such reference. A copy of the registration statement, including the exhibits and schedules thereto, may be read
and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation
of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an internet site
at www.sec.gov, from which interested persons can electronically access the registration statement, including the exhibits and
any schedules thereto.
We are subject to the
information reporting requirements of the Exchange Act, and we file periodic reports and other information with the SEC. All documents
filed with the SEC are available for inspection and copying at the addresses set forth above. We also maintain an internet site
at www.fortressbiotech.com. Our website and the information contained therein or connected thereto shall not be deemed to be incorporated
into this prospectus or the registration statement of which it forms a part.
INCORPORATION OF CERTAIN DOCUMENTS
BY REFERENCE
The SEC allows us to
“incorporate by reference” the information we file with them which means that we can disclose important information
to you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated
by reference is considered to be part of this prospectus, and later information that we file with the SEC will automatically update
and supersede this information. This prospectus incorporates by reference the documents listed below (other than, unless otherwise
specifically indicated, current reports furnished under Item 2.02, Item 7.01 or Item 9.01 of Form 8-K and exhibits filed on such
form that are related to such items):
|
(c)
|
Our Current Report(s) on Form 8-K filed with the SEC on February 12, 2020, March 23, 2020, May 28, 2020, May 29, 2020, June 19, 2020, August 28, 2020 and August 28, 2020 (excluding any information furnished pursuant to Item
2.02 or Item 9.01); and
|
|
(d)
|
The description of the Common Stock as included under the caption “Description of Registrant’s
Securities to be Registered” in our Registration Statements on Form 8-A12B filed with the Commission on December 7, 2011
and November 7, 2017, and any amendment or report filed for the purpose of further updating such descriptions.
|
All reports and other
documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC,
will also be incorporated by reference.
Fortress Biotech,
Inc.
2,100,000 Shares
of Common Stock
PROSPECTUS
,
2020
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance
and Distribution
|
|
Amount to Be Paid
|
|
U.S. Securities and Exchange Commission registration fee
|
|
$
|
549.86
|
|
Legal fees and expenses
|
|
$
|
20,000
|
|
Accounting fees and expenses
|
|
$
|
7,500
|
|
Miscellaneous
|
|
$
|
1,950.14
|
|
Total
|
|
$
|
30,000
|
|
Item 15. Indemnification of Directors
and Officers
Under the General Corporation
Law of the State of Delaware (“DGCL”), a corporation may include provisions in its certificate of incorporation that
will relieve its directors of monetary liability for breaches of their fiduciary duty to the corporation, except under certain
circumstances, including a breach of the director’s duty of loyalty, acts or omissions of the director not in good faith
or which involve intentional misconduct or a knowing violation of law, the approval of an improper payment of a dividend or an
improper purchase by the corporation of stock or any transaction from which the director derived an improper personal benefit.
The Company’s Amended and Restated Certificate of Incorporation eliminates the personal liability of directors to the Company
or its stockholders for monetary damages for breach of fiduciary duty as a director with certain limited exceptions set forth in
the DGCL.
Section 145 of the
DGCL grants to corporations the power to indemnify each officer and director against liabilities and expenses incurred by reason
of the fact that he or she is or was an officer or director of the corporation if he or she acted in good faith and in a manner
he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The Company’s Amended and Restated
Certificate of Incorporation and Bylaws provide for indemnification of each officer and director of the Company to the fullest
extent permitted by the DGCL. Section 145 of the DGCL also empowers corporations to purchase and maintain insurance on behalf of
any person who is or was an officer or director of the corporation against liability asserted against or incurred by him in any
such capacity, whether or not the corporation would have the power to indemnify such officer or director against such liability
under the provisions of Section 145 of the DGCL.
Item 16. Exhibits and Financial Statement
Schedules
The exhibits to the
Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc., filed as Exhibit 3.1 to Form 10-12G on July 15, 2011 (File no. 000-54463) and incorporated herein by reference.**
|
3.2
|
|
First Certificate of Amendment of Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc., filed as Exhibit 3.2 to Form 10-12G on July 15, 2011 (File no. 000-54463) and incorporated herein by reference.**
|
3.3
|
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc., filed as Exhibit 3.1 on the Form 8-K, filed with the Securities and Exchange Commission on June 19, 2020 and incorporated herein by reference.
|
3.4
|
|
Certificate of Amendment to the Certificate of Designations of Rights and Preferences of the Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock under the Amended and Restated Certificate of Incorporation of Fortress Biotech, Inc., filed as Exhibit 3.2 on the Form 8-K filed with the Securities and Exchange Commission on June 19, 2020 and incorporated herein by reference.
|
3.5
|
|
Second Amended and Restated Bylaws of Fortress Biotech, Inc., filed as Exhibit 3.7 to Form 8-K on October 31, 2013 (File no. 001-35366) and incorporated herein by reference.**
|
4.1
|
|
Specimen certificate evidencing shares of common stock, filed as Exhibit 4.1 to Form 10-12G on July 15, 2011 (File no. 000-54463) and incorporated herein by reference.**
|
5.1
|
|
Opinion of Alston & Bird LLP.#
|
23.1
|
|
Consent of BDO USA, LLP, Independent Registered Accounting Firm.#
|
23.2
|
|
Consent of Alston & Bird LLP (to be included in Exhibit 5.1).
|
24.1
|
|
Power of Attorney (included on signature page).
|
25.1
|
|
Statement of Eligibility of Trustee Under Debt Indenture.*
|
|
*
|
To be filed, if necessary, separately pursuant to Section 305(b)(2) of the Trust Indenture Act
of 1939.
|
|
♢
|
To be filed by amendment or as an exhibit to a document to be incorporated by reference herein
in connection with an offering of our securities to the extent applicable.
|
Item 17. Undertakings
|
(a)
|
The undersigned registrant hereby undertakes:
|
|
1.
|
To file, during any period in which offers or sales are being made, a post-effective amendment
to this registration statement:
|
|
(i)
|
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
|
|
(ii)
|
To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum
aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
|
|
(iii)
|
To include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the registration statement;
|
|
2.
|
That, for the purpose of determining any liability under the Securities Act of 1933, each such
post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
|
3.
|
To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering.
|
|
5.
|
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
|
(A) Each prospectus
filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the
filed prospectus was deemed part of and included in the registration statement; and
(B) Each prospectus
required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B
relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required
by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that
is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to
the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
|
6.
|
That, for the purpose of determining liability of the registrant under the Securities Act of 1933
to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used
to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:
|
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering
required to be filed pursuant to Rule 424;
|
|
(ii)
|
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant;
|
|
(iii)
|
The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
|
(iv)
|
Any other communication that is an offer in the offering made by the undersigned registrant to
the purchaser.
|
|
(b)
|
The undersigned registrant hereby undertakes that, for purposes of determining any liability under
the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefits plan’s annual report pursuant to Section
15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
|
|
(c)
|
The undersigned registrant hereby undertakes to supplement the prospectus, after the expiration
of the subscription period, to set forth the results of the subscription offer, the transactions by the underwriters during the
subscription period, the amount of unsubscribed securities to be purchased by the underwriters, and the terms of any subsequent
reoffering thereof. If any public offering by the underwriters is to be made on terms differing from those set forth on the cover
page of the prospectus, a post-effective amendment will be filed to set forth the terms of such offering.
|
|
(e)
|
The undersigned registrant hereby undertakes (1) to use its best efforts to distribute prior to
the opening of bids, to prospective bidders, underwriters, and dealers, a reasonable number of copies of a prospectus which at
that time meets the requirements of section 10(a) of the Act, and relating to the securities offered at competitive bidding, as
contained in the registration statement, together with any supplements thereto, and (2) to file an amendment to the registration
statement reflecting the results of bidding, the terms of the reoffering and related matters to the extent required by the applicable
form, not later than the first use, authorized by the issuer after the opening of bids, of a prospectus relating to the securities
offered at competitive bidding, unless no further public offering of such securities by the issuer and no reoffering of such securities
by the purchasers is proposed to be made.
|
|
(h)
|
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant
has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such
indemnification by it is against public policy as expressed in the Securities Act of 1933, as amended, and will be governed by
the final adjudication of such issue.
|
|
(i)
|
The undersigned registrant hereby undertakes that:
|
|
(1)
|
For purposes of determining any liability under the Securities Act of 1933, the information omitted
from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part
of this registration statement as of the time it was declared effective.
|
|
(2)
|
For the purpose of determining any liability under the Securities Act of 1933, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
FORTRESS BIOTECH, INC.
|
|
|
November 9, 2020
|
By:
|
/s/ Lindsay A. Rosenwald, M.D.
|
|
|
Lindsay A. Rosenwald, M.D.
Chairman, President and Chief Executive
Officer
(Principal Executive Officer)
|
KNOW ALL MEN BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints Lindsay A. Rosenwald, M.D., his true and lawful
attorney-in-fact and agent, with full power of substitution and resubstitution, for him and his name, place and stead, in any and
all capacities, to sign any or all amendments (including pre-effective and post-effective amendments) to this registration statement,
and to file the same, with all exhibits thereto and other documents in connection therewith, including any Registration Statement
filed pursuant to Rule 462(b) under the Securities Act of 1933, with the SEC, granting unto said attorney-in-fact and agent, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent or any of his substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements
of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities
indicated as of November 9, 2020.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Lindsay A. Rosenwald, M.D.
|
|
Chairman of the Board of Directors,
|
|
November 9, 2020
|
Lindsay A. Rosenwald, M.D.
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Robyn M. Hunter
|
|
Chief Financial Officer
|
|
November 9, 2020
|
Robyn M. Hunter
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Eric K. Rowinsky, M.D.
|
|
Vice Chairman of the Board of Directors
|
|
November 9, 2020
|
Eric K. Rowinsky, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
Executive Vice Chairman, Strategic
|
|
November 9, 2020
|
Michael S. Weiss
|
|
Development and Director
|
|
|
|
|
|
|
|
/s/ Jimmie Harvey, Jr., M.D.
|
|
Director
|
|
November 9, 2020
|
Jimmie Harvey, Jr., M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Malcolm Hoenlein
|
|
Director
|
|
November 9, 2020
|
Malcolm Hoenlein
|
|
|
|
|
|
|
|
|
|
/s/ Dov Klein
|
|
Director
|
|
November 9, 2020
|
Dov Klein
|
|
|
|
|
|
|
|
|
|
/s/ J. Jay Lobell
|
|
Director
|
|
November 9, 2020
|
J. Jay Lobell
|
|
|
|
|
|
|
|
|
|
/s/ Kevin L. Lorenz, J.D.
|
|
Director
|
|
November 9, 2020
|
Kevin L. Lorenz, J.D.
|
|
|
|
|
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024